Literature DB >> 19274533

CAP37-derived antimicrobial peptides have in vitro antiviral activity against adenovirus and herpes simplex virus type 1.

Y Jerold Gordon1, Eric G Romanowski, Robert M Q Shanks, Kathleen A Yates, Heather Hinsley, H Anne Pereira.   

Abstract

PURPOSE: The antiviral activity of an established antibacterial CAP37 domain and its extracellular mechanism of action were investigated.
METHODS: CAP37-derived peptides modified to assess the importance of disulfide bonds were evaluated in cytotoxicity and antiviral assays (direct time kill, dose dependency, and TOTO-1) for adenovirus (Ad) and herpes simplex virus type 1 (HSV-1).
RESULTS: Variable virus, adenovirus serotype-dependent, and dose-dependent inhibition were demonstrated without cytotoxicity. For peptide A (CAP37(20-44)), TOTO-1 dye uptake was demonstrated for Ad5 and HSV-1.
CONCLUSIONS: Unlike the antibacterial activity of this CAP37 domain, its antiviral activity is not fully dependent upon disulfide bond formation. Viral inhibition appears to result, in part, from disruption of the envelope and/or capsid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19274533      PMCID: PMC2749063          DOI: 10.1080/02713680802714066

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  35 in total

1.  Antimicrobial peptides of multicellular organisms.

Authors:  Michael Zasloff
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

2.  Peptides containing membrane-transiting motifs inhibit virus entry.

Authors:  Hermann Bultmann; Curtis R Brandt
Journal:  J Biol Chem       Date:  2002-07-18       Impact factor: 5.157

Review 3.  Antibiotic proteins of human neutrophils.

Authors:  J K Spitznagel
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Adenovirus protein VI mediates membrane disruption following capsid disassembly.

Authors:  Christopher M Wiethoff; Harald Wodrich; Larry Gerace; Glen R Nemerow
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Effects of heparin-binding protein (CAP37/azurocidin) in a porcine model of Actinobacillus pleuropneumoniae-induced pneumonia.

Authors:  Brian Lauritzen; Jens Lykkesfeldt; René Djurup; Hans Flodgaard; Ove Svendsen
Journal:  Pharmacol Res       Date:  2005-06       Impact factor: 7.658

Review 6.  Neutrophil serine proteases: specific regulators of inflammation.

Authors:  Christine T N Pham
Journal:  Nat Rev Immunol       Date:  2006-07       Impact factor: 53.106

7.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

8.  Adenovirus-directed ocular innate immunity: the role of conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin-alpha.

Authors:  Stephen A K Harvey; Eric G Romanowski; Kathleen A Yates; Y Jerold Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

9.  Azurocidin, a natural antibiotic from human neutrophils: expression, antimicrobial activity, and secretion.

Authors:  R P Almeida; A Vanet; V Witko-Sarsat; M Melchior; D McCabe; J E Gabay
Journal:  Protein Expr Purif       Date:  1996-06       Impact factor: 1.650

10.  NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2.

Authors:  Sara Sinha; Natalia Cheshenko; Robert I Lehrer; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  8 in total

1.  Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.

Authors:  Zhenping Wang; Yuping Lai; Jamie J Bernard; Daniel T Macleod; Anna L Cogen; Bernard Moss; Anna Di Nardo
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

Review 2.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

3.  Maternal vitamin D supplementation during pregnancy and lactation to prevent acute respiratory infections in infancy in Dhaka, Bangladesh (MDARI trial): protocol for a prospective cohort study nested within a randomized controlled trial.

Authors:  Shaun K Morris; Lisa G Pell; Mohammed Ziaur Rahman; Michelle C Dimitris; Abdullah Mahmud; M Munirul Islam; Tahmeed Ahmed; Eleanor Pullenayegum; Tahmid Kashem; Shaila S Shanta; Jonathan Gubbay; Eszter Papp; Michelle Science; Stanley Zlotkin; Daniel E Roth
Journal:  BMC Pregnancy Childbirth       Date:  2016-10-13       Impact factor: 3.007

Review 4.  Human Antimicrobial Peptides in Bodily Fluids: Current Knowledge and Therapeutic Perspectives in the Postantibiotic Era.

Authors:  Paulo Bastos; Fábio Trindade; João da Costa; Rita Ferreira; Rui Vitorino
Journal:  Med Res Rev       Date:  2017-01-17       Impact factor: 12.944

5.  Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents.

Authors:  Michelle Science; Jonathon L Maguire; Margaret L Russell; Marek Smieja; Stephen D Walter; Mark Loeb
Journal:  Clin Infect Dis       Date:  2013-05-15       Impact factor: 9.079

Review 6.  Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Authors:  Kelly C L Mulder; Loiane A Lima; Vivian J Miranda; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2013-10-31       Impact factor: 5.640

7.  Antimicrobial peptides: versatile biological properties.

Authors:  Muthuirulan Pushpanathan; Paramasamy Gunasekaran; Jeyaprakash Rajendhran
Journal:  Int J Pept       Date:  2013-06-26

Review 8.  Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.

Authors:  Anja Pfalzgraff; Klaus Brandenburg; Günther Weindl
Journal:  Front Pharmacol       Date:  2018-03-28       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.